Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.1239
- -0.0100-7.47%
Close Feb 25 16:00 ET
- 0.1229
- -0.0010-0.81%
Post 20:01 ET
8.52MMarket Cap-0.26P/E (TTM)
0.1350High0.1105Low942.86KVolume0.1350Open0.1339Pre Close115.91KTurnover1.59%Turnover RatioLossP/E (Static)68.75MShares0.620052wk High2.95P/B7.33MFloat Cap0.110552wk Low--Dividend TTM59.18MShs Float836.0000Historical High--Div YieldTTM18.30%Amplitude0.1105Historical Low0.1220Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
AIM ImmunoTech Stock Forum
extracted from X, NFA
Our lead program is an immuno-modulator that has shown positive data published in
numerous well-respected journals and forums. Learn more: bit.ly/4gzyqnz
AIM ImmunoTech Announces That It Will Not Proceed With an Offering Pursuant to Its Registration Statement on Form S-1 Until After It Files Its Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Friday, 7th February at 8:50 am
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priorit...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
AIM had news and didn't run which also happened with IVVD and CPIX. Both were held down, shorted and eventually ran. They ran the same day though so not sure about AIM but worth the watch!
$AIM ImmunoTech (AIM.US)$
I still have my eyes on KTTA - news was released today and it didn't really run. It got beaten down so could still see its day, or maybe not lol.
$Pasithea Therapeutics (KTTA.US)$
Remember, chasing is a dangerous game. Be very selective with...
No comment yet